C형 간염 치료제 시장 : 약물 종류별, 투여 경로별, 유통 채널별, 지역별
Hepatitis C Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography
상품코드
:
1707404
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
C형 간염 치료제 세계 시장은 2025년에 98억 6,000만 달러로 추정되며, 2032년에는 132억 4,000만 달러에 달할 것으로 예상되며, 2025년부터 2032년까지 CAGR 4.3%로 성장할 것으로 예상됩니다.
| 보고서 범위 |
보고서 상세 |
| 기준 연도 |
2024년 |
2025년 시장 규모 |
98억 6,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간 : 2025-2032년 CAGR: |
4.30% |
2032년 가치 예측 |
132억 4,000만 달러 |
그림. C형 간염 치료제 시장 점유율(%), 지역별, 2025년
C형 간염은 C형 간염 바이러스에 의해 발생하는 심각한 간 손상을 유발하는 간 감염 질환입니다. 미국에서는 약 240만 명이 앓고 있습니다. 그러나 C형 간염은 증상이 거의 나타나지 않기 때문에 대부분 자각증상이 없습니다. 바이러스는 감염자의 혈액이나 체액을 통해 전파됩니다.
C형 간염의 잠복기. 최초 노출 후 발병까지의 기간입니다. 잠복기는 14-80일이며, 평균 45일입니다. 급성 C형 간염 : 바이러스가 체내에 들어온 후 6개월 동안 지속되는 단기 질환입니다. 만성 C형 간염 : C형 간염에 걸린 대부분의 사람들(85%까지)은 만성 C형 간염에 걸리면 병이 오래 지속되는 단계(6개월 이상)로 넘어가게 됩니다. 이를 만성 C형 간염 감염이라고 하며, 간암이나 간경변과 같은 심각한 건강 문제로 이어질 수 있습니다. 간경변증. 이 질병은 염증을 유발하고 시간이 지남에 따라 건강한 간세포가 흉터 조직으로 대체됩니다. 술을 마시거나 HIV에 감염되면 간경변증이 더 빨리 발생할 수 있지만, 일반적으로 간경변증은 약 20-30년 정도 걸립니다.
시장 역학:
C형 간염의 세계 유병률 증가는 예측 기간 동안 시장 성장에 도움이 될 것으로 예상됩니다. 예를 들어, 2021년 9월 18일 National Center for Biotechnology Information이 발표한 자료에 따르면, 인도의 HCV 유병률은 0.5%로 약 470만 명에서 1,090만 명이 앓고 있는 것으로 나타났습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 세계에서 C형 간염 만연이 증가
- 정부 이니셔티브 강화
- 부작용 증가
- 다양한 지역에서의 제품 입수 가능성 향상
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER의 분석
- 인수합병 시나리오
제4장 C형 간염 치료제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측 분석
- 경제에 대한 영향
제5장 C형 간염 치료제 시장, 약물 종류별, 2020-2032년
- NS3/4A 프로테아제 억제제
- NS5A 억제제
- NS5B 폴리메라아제 억제제
- 복합제
- 기타
제6장 C형 간염 치료제 시장, 투여 경로별, 2020-2032년
제7장 C형 간염 치료제 시장, 유통 채널별, 2020-2032년
제8장 C형 간염 치료제 시장, 지역별, 2020-2032년
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제9장 경쟁 구도
- Gilead Sciences
- AbbVie
- Merck & Co
- Bristol-Myers Squibb
- Johnson & Johnson
- Hoffmann-La Roche AG
- Boehringer Ingelheim
- Achillion Pharmaceuticals
제10장 섹션
ksm
영문 목차
Global Hepatitis C Drugs Market is estimated to be valued at USD 9.86 Bn in 2025 and is expected to reach USD 13.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 9.86 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
4.30% |
2032 Value Projection: |
USD 13.24 Bn |
Figure. Hepatitis C Drugs Market Share (%), By Region 2025
Hepatitis C is a liver infection that can lead to serious liver damage. It's caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person's blood or body fluids.
Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C - up to 85% - the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.
Market Dynamics:
The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.
Hepatitis C Drugs Market Segmentation:
- By Drug Class
- NS3/4A Protease Inhibitors
- NS5A Inhibitors
- NS5B Polymerase Inhibitors
- Combination Drugs
- Others
- By Route of Administration
- Oral Drugs
- Intravenous
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Gilead Sciences
- AbbVie
- Merck & Co
- Bristol-Myers Squibb
- Johnson & Johnson
- Hoffmann-La Roche AG
- Boehringer Ingelheim
- Achillion Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Growing Prevalence of Hepatitis C Globally
- Increasing Government Initiatives
- Increasing Adverse Effects
- Increasing Product Availability in Various Regions
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Hepatitis C Drugs Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Hepatitis C Drugs Market, By Drug Class, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- NS3/4A Protease Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- NS5B Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Combination Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Hepatitis C Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Oral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
7. Hepatitis C Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
8. Hepatitis C Drugs Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2025and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- China
- Japan
- India
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Achillion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
관련자료
